Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.
about
Korean clinical practice guideline for benign prostatic hyperplasiaUpdate on medical therapy for male LUTSThe pathophysiology of delayed ejaculationBest of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.Role of 5α-reductase inhibitors in benign prostatic diseases.Dutasteride for the treatment of benign prostatic hyperplasia.Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year rEmerging drug therapies for benign prostatic hyperplasia.The role of combination medical therapy in benign prostatic hyperplasia.5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability.Altering disease progression: the key to successful patient management.The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia.Urologic medications and ophthalmologic side effects: a review.Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.Identification of the patient with enlarged prostate: diagnosis and guidelines for management.Cataract surgery in patients taking alpha-1 antagonists: know the risks, avoid the complicationsBenign prostatic hyperplasia: an insight into current investigational medical therapies.Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itDutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.The Canadian Benign Prostatic Hyperplasia Audit Study (CanBas).5alpha-reductase inhibition for men with enlarged prostate.Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ERβ) Response to 5α-Reductase Inhibition in Prostate Epithelial Cells.Finasteride in the treatment of patients with benign prostatic hyperplasia: a reviewEmerging drugs for the treatment of benign prostatic obstruction.Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Current pharmacological treatment options for male lower urinary tract symptoms.Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study.Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic HyperplasiaFinasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers.Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).Outline of JUA clinical guidelines for benign prostatic hyperplasia.Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
P2860
Q26766302-F8D5DE3F-1E84-4638-A53F-FA4AD6206ACEQ26862710-BD2EE26E-D475-44A1-BFF4-7FE9805BF242Q28074466-E0AB4DEE-568A-4768-BCD1-CFE981126083Q33302509-EB71C100-B3C8-49DB-87FB-45C754C4E04BQ33602452-8FF673FF-6ECF-40E6-9850-04B9F35F0D6CQ33797223-6CEF4A10-373E-41E9-B450-BC9F7B5C869CQ34254296-FC4F0DBD-0998-400E-9A6E-BBF94A2E55CAQ34349726-52B067C3-1352-49A5-87E5-B7AD7319000CQ34377799-B7566301-2C0B-4C6A-B298-28F5B1E7688DQ34565171-C5719238-652B-4F1A-A7E1-E5E1CFAB6B3BQ34877827-BF8A252C-9537-46BB-89FC-41409886948AQ34887797-A8137DA1-DD6C-41EA-904D-886634530E44Q35152005-A7F98EC7-E82C-4BBE-8CF5-AB5817CC1525Q35328005-0069A55F-529B-4162-9A20-45C2B3EE9D0EQ35685859-CCB32818-EC55-4D5B-8752-FB9C7BE8B469Q35685864-B1AA8F02-6834-44EC-B632-92B956CAA727Q35788323-154E6786-46EB-427C-8573-C9E5FA6CC1F7Q35876383-9B350E85-E84D-4211-86F9-78AB63495898Q35945368-DCC6D085-16D6-41F4-9177-7ED04FDAE926Q36021483-D7219600-708C-431C-A3FF-B80AAED89E91Q36300022-D970A3CD-04CF-4339-8854-561640AB1DA0Q36379355-3A7BCEF9-9136-497E-9FFD-B116AB7EF56CQ36434305-75883557-1911-4C05-919B-4492BE243FB1Q36498032-78AD9BD6-E7C2-4338-8B50-D7B5202C6DCDQ36737065-D25A80D9-5E09-41C0-92B7-3905096081EBQ36867891-3A5DFCE9-E67A-43DA-88AE-8C50DF8DA958Q36892851-21181E72-149E-466F-ABE0-D9A9743DFFC6Q37078703-92F5F80C-8F07-442C-A2F3-A99CB81F2C58Q37261063-8CEEA8EC-0116-4D5B-B225-F5A2ACDC1B63Q37743490-EC938FB0-8FCA-4770-A747-A12096905FCAQ37790387-4790C7E1-47C3-4A72-B955-A1B81997C3D3Q38103891-40029A6F-48D9-4C0C-9CF6-B6D88CC240A0Q38118357-C082164E-33E6-45FF-BF63-51EB1D5F52E4Q38136528-B76D28EC-37E8-4256-B0D7-02B98B04736BQ38466939-7933EAE0-7F18-4851-847C-C95871226496Q38468579-59FD3CF7-0EB0-4445-ABF4-E542FFB6C9F3Q39020100-92D0E025-FEAC-42CD-8D34-3C019A78F4C4Q39216105-B533A444-C198-40D4-9FEB-9FDCDD49A8E9Q39256832-4F9259D4-0ABC-406A-99A1-19ECDC7B2EE0Q39467333-C287CC4F-28E5-43BB-8D75-C5B62039197E
P2860
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@ast
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@en
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@nl
type
label
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@ast
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@en
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@nl
prefLabel
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@ast
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@en
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@nl
P2093
P1433
P1476
Alpha-blocker therapy can be w ...... ductase inhibitor dutasteride.
@en
P2093
Guimarães M
van Vierssen Trip OB
P304
P356
10.1016/S0302-2838(03)00367-1
P407
P577
2003-10-01T00:00:00Z